Proton pump inhibitor use is associated with increased risk of severity and mortality from coronavirus disease 2019 (COVID-19) infection

[1]  C. Chelala,et al.  COVID-19 in patients with hepatobiliary and pancreatic diseases in East London: A single-centre cohort study , 2020, medRxiv.

[2]  A. Kurniawan,et al.  Statin therapy did not improve the in-hospital outcome of coronavirus disease 2019 (COVID-19) infection , 2020, Diabetes & Metabolic Syndrome: Clinical Research & Reviews.

[3]  A. Kurniawan,et al.  Metformin use is associated with reduced mortality rate from coronavirus disease 2019 (COVID-19) infection , 2020, Obesity Medicine.

[4]  E. K. Ha,et al.  Severe clinical outcomes of COVID-19 associated with proton pump inhibitors: a nationwide cohort study with propensity score matching , 2020, Gut.

[5]  P. McKeigue,et al.  Associations of severe COVID-19 with polypharmacy in the REACT-SCOT case-control study , 2020, medRxiv.

[6]  H. Goyal,et al.  Prehospitalization Proton Pump Inhibitor (PPI) use and Clinical Outcomes in COVID-19 , 2020, medRxiv.

[7]  J. Dibner.  Fecal‐oral transmission of COVID‐19: Could hypochlorhydria play a role? , 2020, Journal of medical virology.

[8]  D. Bettinger,et al.  Treatment with proton pump inhibitors increases the risk of secondary infections and ARDS in hospitalized patients with COVID‐19: coincidence or underestimated risk factor? , 2020, Journal of internal medicine.

[9]  R. Pranata,et al.  The use of renin angiotensin system inhibitor on mortality in patients with coronavirus disease 2019 (COVID-19): A systematic review and meta-analysis , 2020, Diabetes & Metabolic Syndrome: Clinical Research & Reviews.

[10]  E. Savarino,et al.  Latest insights into the hot question of proton pump inhibitor safety - a narrative review. , 2020, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[11]  Soumitra Sengupta,et al.  Characterization and clinical course of 1000 patients with coronavirus disease 2019 in New York: retrospective case series , 2020, BMJ.

[12]  Chien-Chang Lee,et al.  Proton pump inhibitors therapy and the risk of pneumonia: a systematic review and meta‐analysis of randomized controlled trials and observational studies , 2019, Expert opinion on drug safety.

[13]  S. Tagliaferri,et al.  Adverse Events of Proton Pump Inhibitors: Potential Mechanisms. , 2017, Current drug metabolism.

[14]  E. Savarino,et al.  Are proton pump inhibitors really so dangerous? , 2016, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[15]  G. Sachs,et al.  Pharmacology of proton pump inhibitors , 2008, Current gastroenterology reports.

[16]  M. Namazi,et al.  A succinct review of the general and immunological pharmacologic effects of proton pump inhibitors , 2008, Journal of clinical pharmacy and therapeutics.

[17]  D. Forman,et al.  The efficacy of proton pump inhibitors in nonulcer dyspepsia: a systematic review and economic analysis. , 2004, Gastroenterology.